Innexus Nutraceuticals is developing an exciting line of nutraceuticals that address various indications and target different physiologic areas. This includes gut health, nervous system health, and a spectrum of inflammation-based and, pain disorders.
OptiPEA® – Palmitoylethanolamide (PEA)
OptiPEA® is a registered logo and trademark, representing high-quality PEA. OptiPEA® is developed for the use in food supplements. A lot of time has been invested in the development of OptiPEA®. Our multidisciplinary team of PhD chemists, qualified manufacturers and food experts have enabled us to create a premium raw material. We believe this is of utmost importance for a natural nutraceutical such as PEA which is usually used for longer periods of time.
PEA is a bioactive functional lipid that belongs to a class of molecules known as fatty acid amides. PEA is a naturally occurring compound that dates back hundreds of millions of years up the evolutionary path and is found in plant and animal cells. This lipid has anti-inflammatory as well as pain-relieving properties. It acts as a protective and repairing molecule supporting the self-healing ability of the body.
Visit www.optipea.com for more information.
Most probiotic culturing technologies are based on manufacturing methods involving the microorganisms being grown as individual strains in a sterile environment. After freeze drying, dormant individual strains are blended into a formulation.
The strains never have the opportunity to interact with each other during the culture phase until digested. Our probiotic development is fundamentally different as our microorganisms, which include both bacteria and yeast species, are grown together during the culture phase. They are able to form a small eco system while they are nourished throughout the manufacturing process.
Each individual strain develops while interacting with all co-present others which results in a stronger, more potent and extremely broad spectrum probiotic. This culturing technology is designed to mimic the way microorganisms survive in natural environments where microbial strains never exist in isolation or pure culture.
There is a lot of evidence that the endocannabinoid system cannot only be activated with compounds that directly target the CB1 and/or CB2 receptors but also with inhibitors of endocannabinoid cellular uptake, as well as the intracellular metabolism of endocannabinoids. Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) are the target enzymes for the latter mechanisms.
Phytocannabinoids have peaked our specific interest as they are able to augment endocannabinoid levels or inhibit these processes by activating enzymes in a manner that enhances endocannabinoid release.
We have a number of candidate nutraceuticals on file that would be able to interact with the endocannabinoid system in specific and controlled manners.